1. Home
  2. DOGZ vs IKT Comparison

DOGZ vs IKT Comparison

Compare DOGZ & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DOGZ

Dogness (International) Corporation

HOLD

Current Price

$10.61

Market Cap

153.5M

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$1.62

Market Cap

181.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DOGZ
IKT
Founded
2003
2008
Country
China
United States
Employees
N/A
N/A
Industry
Miscellaneous manufacturing industries
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
153.5M
181.9M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
DOGZ
IKT
Price
$10.61
$1.62
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$4.00
AVG Volume (30 Days)
140.5K
428.3K
Earning Date
10-17-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$20,707,707.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
39.47
N/A
52 Week Low
$6.81
$1.33
52 Week High
$53.25
$4.20

Technical Indicators

Market Signals
Indicator
DOGZ
IKT
Relative Strength Index (RSI) 35.21 58.23
Support Level $10.60 $1.43
Resistance Level $11.74 $1.57
Average True Range (ATR) 0.62 0.09
MACD -0.08 0.01
Stochastic Oscillator 1.72 89.80

Price Performance

Historical Comparison
DOGZ
IKT

About DOGZ Dogness (International) Corporation

Dogness (International) Corp designs, manufactures pet products, including leashes and smart products, and lanyards. The company designs, processes, and manufactures fashionable and high-quality leashes, collars, and harnesses to complement cats' and dogs' appearances, as well as intelligent pet products. The company also provides dyeing services to external customers, as well as pet grooming services. The dyeing service is to utilize the existing production capacity and the pet grooming service is immaterial. Geographically, it generates maximum revenue from Mainland China and also has a presence in the United States, Europe, Australia, Canada, Central, and South America, Japan, and other Asian countries and regions.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Share on Social Networks: